Name: World Health Day 2025: Why Your Dental Health Is Important, An Exclusive Conversation With Lt Gen Dr Vimal Arora
Uploaded: 2025-04-07T10:37:28+05:30
Duration: 27 min 32 s
Description: Every year on April 7, World Health Day is observed, this year, our team in an exclusive interview with Lt Gen Dr Vimal Arora spoke to him about the importance of dental health and how it can tell a lot about your overall health. As Dr Arora rightly says, your oral health is like a "mirror" to your overall health. Watch the full interview here.

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Health and Me

Health Conditions A-Z

Health & Wellness

Nutrition

Fitness

Health News

Ayurveda

Videos

Medicine A-Z

Checkups & Vaccinations

Care & Precautions

Diet & Nutrition

Infant 0 - 1 Year

Toddler 2-4 Years

Kid 5- 8 Years

Pre-Teen 9-12 Years

Checkups & Vaccination

Teen 13 - 19 Years

Parenting

Ishita Roy

Health

Healthcare

dentistry

oral health

dental care

implants

gum disease

saliva

cavities

dental floss

World Health Day

Every year on April 7, World Health Day is observed, this year, our team in an exclusive interview with Lt Gen Dr Vimal Arora spoke to him about the importance of dental health and how it can tell a lot about your overall health. As Dr Arora rightly says, your oral health is like a "mirror" to your overall health. Watch the full interview here.

World Health Day 2025: Why Your Dental Health Is Important, An Exclusive Conversation With Lt Gen Dr Vimal Arora

world health day 2025: why your dental health is important, an exclusive conversation with lt gen dr vimal arora

COVID-19 In India: Omicron RF.5 Primarily Affects Throat, Unlikely To Trigger Pneumonia In Healthy People, Say Experts

covid-19 in india: omicron rf.5 primarily affects throat, unlikely to trigger pneumonia in healthy people, say experts

India Logs 339 COVID-19 Cases In First Half Of July: What To Know About The RF.5 Omicron Subvariant

india logs 339 covid-19 cases in first half of july: what to know about the rf.5 omicron subvariant

Why Transporting Ebola Victims' Bodies Is Fueling Congo's Outbreak, UN Agency Issues Warning

why transporting ebola victims' bodies is fueling congo's outbreak, un agency issues warning

US Reports 2,260 Measles Cases In Just Over Six Months Of 2026: CDC

us reports 2,260 measles cases in just over six months of 2026: cdc

covid19

coronavirus india

covid deaths in andhra pradesh

covid

covid booster

covid booster shot

coronavirus

COVID-19 cases are once again drawing attention after Andhra Pradesh reported four deaths among people who tested positive for the virus between June 26 and July 16. Although the total number of cases remains low, health experts say the geographical spread across multiple districts raises important questions.

Do You Need Another COVID Booster Shot? Experts Answer After 4 COVID Deaths In Andhra Pradesh

do you need another covid booster shot? experts answer after 4 covid deaths in andhra pradesh

Common Antidepressant May Ease One Of Long COVID's Debilitating Symptoms, Landmark Trial Suggests

common antidepressant may ease one of long covid's debilitating symptoms, landmark trial suggests

ICMR Study Highlights India’s Silent Cholesterol Crisis: 9 In 10 Adults Have At Least One Abnormal Blood Lipid

icmr study highlights india’s silent cholesterol crisis: 9 in 10 adults have at least one abnormal blood lipid

covid india

covid deaths india

covid update india

india covid cases

andhra pradesh covid

andhra covid deaths

COVID-19 infections are once again making headlines in India after Andhra Pradesh reported three COVID-19 positive deaths and several fresh cases.Health authorities in Andhra Pradesh, Odisha, and Tamil Nadu have increased surveillance measures as experts monitor the situation closely. While the exact variant responsible for the recent cases is still being identified through genome sequencing, doctors say Omicron sub-lineages continue to dominate and are generally associated with milder illness.However, severe disease remains possible, particularly among older adults, people with diabetes, heart disease, chronic lung or kidney conditions, cancer patients, pregnant women, and those with weakened immune systems.

COVID-19 Cases Surging Again In India: 3 Deaths Reported In Andhra Pradesh | Who Is Most At Risk?

covid-19 cases surging again in india: 3 deaths reported in andhra pradesh | who is most at risk?

Coffee Is Good For The Heart, But Your Choice Of Brew May Raise Bad Cholesterol: American Heart Association

coffee is good for the heart, but your choice of brew may raise bad cholesterol: american heart association

Excessive TV Watching In Midlife May Shrink Brain Areas Essential For Memory, Study Finds

excessive tv watching in midlife may shrink brain areas essential for memory, study finds

PMOS Raises Risk Of Heart Attacks, Strokes In Young Women: Lancet Study

pmos raises risk of heart attacks, strokes in young women: lancet study

US Obesity Crisis: Not Losing Weight Despite Hitting The Gym? New AHA Study Reveals Why

us obesity crisis: not losing weight despite hitting the gym? new aha study reveals why

why is yawning contagious

mirror neurons explained

brain facts

why do people yawn when others yawn

contagious yawning explained

science of yawning

psychology facts

Have you ever started yawning just because someone sitting next to you did?

Why Do We Yawn When Others Yawn? A Psychiatrist Explains the Science

why do we yawn when others yawn? a psychiatrist explains the science

Health Dept Ramps Up Efforts As Malaria, Dengue Cases Increase In Ludhiana; How To Prevent

health dept ramps up efforts as malaria, dengue cases increase in ludhiana; how to prevent

High-Risk Pregnancy: Recognizing The Warning Signs Before They Become Emergencies

high-risk pregnancy: recognizing the warning signs before they become emergencies

As Sonam Wangchuk's Indefinite Fast Continues, Doctors Explain When Hunger Strike Becomes Medically Dangerous

as sonam wangchuk indefinite fast continues, doctors explain when hunger strike becomes medically dangerous

paracetamol

paracetamol side effects

paracetamol overdose

paracetamol safety

safe paracetamol dose

Paracetamol is one of the most commonly used medicines worldwide for fever, headaches, body aches, and pain relief. When taken at the recommended dose, it is considered safe for most people. But doctors say many people unknowingly make one common mistake that can increase the risk of serious complications.

Before You Take Another Paracetamol, Watch This | Doctors Explain the Hidden Risk

before you take another paracetamol, watch this | doctors explain the hidden risk

India Vaccinates Over 5.2 Million Girls Against HPV To Fight Cervical Cancer

Rachel V Thomas

india-vaccinates-over-52-million-girls-against-hpv-to-fight-cervical-cancer

Cervical Cancer

HPV Vaccine

cervical cancer decline in India

Human Papillomavirus

HPV vaccination campaign

Pandemic Preparedness

A total of 52,10,302 girls across India have received the Human Papillomavirus (HPV) vaccine under the nationwide campaign launched by Prime Minister Narendra Modi in February, the government informed Parliament during the ongoing Monsoon Session. The <a href="https://www.healthandme.com/health-news/pm-modi-launches-nationwide-free-hpv-vaccination-drive-a-landmark-step-says-who-article-153717823" data-type="tilCustomLink">nationwide vaccination campaign</a> for 14-year-old girls was launched from Rajasthan's Ajmer as part of India's efforts to eliminate cervical cancer. “The nationwide HPV vaccination campaign was launched on February 28, for approximately 1.2 crore eligible beneficiary girls aged 14 years across all 36 States and Union Territories. As of July 15, a total of 52,10,302 girls have received the HPV vaccine across the country,” Union Minister of State for Health and Family Welfare Anupriya Patel said in a written reply in the Rajya Sabha. <h2>Free HPV Vaccination</h2> Read More: <a href="https://www.healthandme.com/health-news/fact-check-common-myths-around-hpv-vaccine-and-how-it-will-prevent-cervical-cancer-article-153720030" data-type="tilCustomLink">Fact Check: Common Myths Around HPV Vaccine And How It Will Prevent Cervical Cancer</a> The Minister said the HPV vaccine is being provided free of cost at designated government health facilities, including: <ul><li>Ayushman Arogya Mandirs–Primary Health Centers (PHCs) </li></ul><ul><li>Community Health Centers (CHCs) </li></ul><ul><li>Sub-District Hospitals (SDHs) and District Hospitals (DHs) </li></ul><ul><li>Government Medical Colleges (GMCs) </li></ul>Patel added that extensive training on HPV vaccination has been completed for medical and paramedical staff across all 36 States and Union Territories. She also said the government's cervical cancer prevention strategy includes HPV vaccination, screening, early diagnosis at Ayushman Arogya Mandirs (AAMs), and treatment through Day Care Cancer Centers (DCCCs). <h2>Immunization Coverage Remains Above 90% </h2> The Minister also updated Parliament on India's immunization program. “As per the National Health Policy 2017 goals, the National Full Immunization Coverage has been maintained more than 90% for the last four years,” Patel said. National full immunization coverage was: <ul><li>94.7% in 2022–23 </li></ul><ul><li>93.7% in 2023–24 </li></ul><ul><li>98.3% in 2024–25 </li></ul><ul><li>97.9% in 2025–26 </li></ul> <h2>Strengthening Pandemic Preparedness </h2> Also read: <a href="https://www.healthandme.com/health-news/healthcare-in-india-no-longer-a-privilege-becoming-a-right-pm-modi-article-155117584" data-type="tilCustomLink">Healthcare In India No Longer A Privilege, Becoming A Right: PM Modi</a> Patel also said that the government has taken several steps to improve preparedness for future pandemics and public health emergencies, including: <ul><li>Launch of the Pradhan Mantri-Ayushman Bharat Health Infrastructure Mission (PM-ABHIM) to strengthen public health infrastructure, disease surveillance, diagnostics, research, and emergency response. </li></ul><ul><li>Strengthening the Integrated Disease Surveillance Program (IDSP) with trained multidisciplinary Rapid Response Teams (RRTs). </li></ul><ul><li>Expansion of the Indian Council of Medical Research's Virus Research and Diagnostic Laboratory (VRDL) network to more than 160 laboratories for pathogen diagnosis. </li></ul> Meanwhile, the Nationwide Viral Research and Diagnostic Laboratories (VRDL) network under ICMR has been expanded to 163 laboratories, comprising 11 Regional VRDLs, 27 State VRDLs and 125 Medical College VRDLs, to strengthen diagnostic capacity across the country. <h2>Cervical Cancer Cases Decline </h2> Read to Know: <a href="https://www.healthandme.com/health-news/sheta2-indias-indigenous-drug-candidate-for-cervical-cancer-article-155145497" data-type="tilCustomLink">SHetA2: India's Indigenous Drug Candidate For Cervical Cancer</a> Meanwhile, recent data from the ICMR's National Cancer Registry Program (NCRP) show that India has recorded a significant decline in its cervical cancer burden. According to the latest estimates, new cervical cancer cases have fallen by 37% over the past decade, declining from about 1.27 lakh cases annually to around 79,000, marking a major public health milestone in the fight against one of the country's most common cancers among women. Unlike many other cancers, cervical cancer is considered highly preventable through HPV vaccination, regular screening, and timely treatment of precancerous lesions. The WHO global targets for 2030 include vaccinating 90 percent of girls by age 15, screening 70 percent of women by ages 35 and 45, and ensuring 90 percent of women with pre-cancer and invasive cancer receive appropriate treatment. <meta content="cms.next" name="cmsei" />

india vaccinates over 5.2 million girls against hpv to fight cervical cancer

IIT Kanpur Scientists Reveal How Experimental Vaccine Booster Activates Immune System

Nisha Pandey

iit-kanpur-scientists-reveal-how-experimental-vaccine-booster-activates-immune-system

IIT Kanpur Scientists Reveal How Experimental Vaccine Booster Activates Immune System, Encourage Safer Vaccines

kanpur

iit kanpur

national academy of sciences

staphylococcus aureus

indian institute of technology

Vaccine Booster

Immune System

Researchers at the Indian Institute of Technology (IIT) Kanpur have uncovered how an experimental vaccine booster molecule activates the body's immune system, a breakthrough that could help researchers develop safer and more effective vaccines in the future. The study, published this month in the Proceedings of the National Academy of Sciences (PNAS), provides the first detailed structural view of how a synthetic molecule called EP67 binds to and activates an important immune receptor known as C5aR1. The findings offer researchers a molecular blueprint for improving vaccine adjuvants, the ingredients added to vaccines to strengthen and prolong immune protection. Unlike vaccines, which train the immune system to recognize a specific pathogen, adjuvants help amplify the body's immune response, making vaccines more effective. <h2>Inspired By The Body's Natural Immune System </h2> Also read: <a href="https://www.healthandme.com/health-news/us-reports-2260-measles-cases-in-just-over-six-months-of-2026-cdc-article-155145602" data-type="tilCustomLink">US Reports 2,260 Measles Cases In Just Over Six Months Of 2026: CDC</a> The researchers developed <a href="https://www.healthandme.com/health-news/indias-first-approved-dengue-vaccine-takedas-qdenga-protects-against-all-four-virus-serotypes-article-155137910" data-type="tilCustomLink">EP67</a> by taking inspiration from C5a, a naturally occurring immune protein released during bacterial and viral infections. While C5a helps activate immune cells to fight infections, prolonged activation can trigger harmful inflammation and damage healthy tissues. To overcome this challenge, the IIT Kanpur team engineered EP67, a much smaller version consisting of just 10 amino acids. The molecule retains the beneficial immune-stimulating properties of C5a while limiting the inflammatory effects. According to the researchers, EP67 selectively activates dendritic cells and macrophages, two immune cells that play a central role in generating long-lasting immunity, while largely avoiding activation of neutrophils, immune cells that are often responsible for excessive inflammatory responses. This selective activation makes EP67 a promising candidate as a vaccine adjuvant capable of producing stronger immune protection without triggering inflammation. <h2>Earlier Studies </h2> <div type="Youtube" id="k2OnYNIwo4I" title="COVID-19 Cases Surging Again In India: 3 Deaths Reported In Andhra Pradesh | Who Is Most At Risk?" thumbUrl="https://i.ytimg.com/vi/k2OnYNIwo4I/mqdefault.jpg"><url><![CDATA[https://www.youtube.com/watch?v=k2OnYNIwo4I]]></url></div> Previous animal studies have shown the potential of EP67 in boosting vaccine responses. When incorporated into experimental vaccines against multiple viruses, including SARS-CoV-2, the virus responsible for <a href="https://www.healthandme.com/health-wellness/covid-19-in-india-omicron-rf-5-primarily-affects-throat-unlikely-to-trigger-pneumonia-in-healthy-people-say-experts-article-155138964" data-type="tilCustomLink">COVID-19</a>, mice developed stronger immune responses than those receiving vaccines alone. Researchers also observed faster recovery in infected animals. Beyond vaccines, EP67 has also shown promise against bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA), a major antibiotic-resistant pathogen. However, the molecule has not yet entered clinical use in humans, and additional preclinical research will be required before human trials can begin. Although scientists had previously observed EP67's immune-boosting effects, precisely how the molecule worked remained vague for a long time. The IIT Kanpur researchers found that EP67 binds to C5aR1, a receptor located on the surface of immune cells. C5aR1 belongs to the large family of G protein-coupled receptors (GPCRs), which are involved in transmitting signals into cells and are among the most common targets for modern medicines. Using cryo-electron microscopy (cryo-EM), the team captured near-atomic-resolution images showing EP67 adopting a hook-like shape that fits into the centre of the receptor, switching it on and initiating immune activation. The structural insights have already enabled researchers to redesign EP67 by modifying its amino acid sequence to improve its stability and receptor binding. The next steps would be refining the formulation and introducing it in pre-clinical tests.<meta content="cms.next" name="cmsei" />

iit kanpur scientists reveal how experimental vaccine booster activates immune system, encourage safer vaccines

Do People With Type 2 Diabetes Face a Higher Risk of Severe Dengue? New Review Says Yes

do-people-with-type-2-diabetes-face-a-higher-risk-of-severe-dengue-new-review-says-yes

Do People With Type 2 Diabetes Face A Higher Risk of Severe Dengue? New Review Says Yes

type 2 diabetes

dengue

dengue vaccine

QDENGA

TAK 003

diabetes and dengue

People living with Type 2 diabetes may be significantly more vulnerable to severe, potentially life-threatening complications from dengue, according to a new review by diabetes specialists. The paper, presented in July 2026 and slated for publication in the International Journal of Diabetes &amp; Technology (IJDT), also recommends combining dengue vaccination into routine diabetes care in dengue-endemic regions to better protect patients who are at high risk. The review comes as many countries, including India, continue to witness surges in dengue cases during the monsoon months. <h2>Can Type 2 Diabetes Make Dengue More Severe? </h2> Also read: <a href="https://www.healthandme.com/health-news/will-waterborne-diseases-rise-in-the-future-new-study-says-climate-change-could-be-a-major-driver-article-155134094" data-type="tilCustomLink">Will Waterborne Diseases Rise In The Future? New Study Says Climate Change Could Be A Major Driver</a> According to the researchers, chronic high blood sugar weakens the immune system and damages blood vessels, making it harder for the body to fight <a href="https://www.healthandme.com/health-wellness/monsoon-playbook-for-parents-common-home-mistakes-that-increase-infection-risk-in-children-article-155037540" data-type="tilCustomLink">dengue infection</a>. It increases the risk of vascular leakage, severe bleeding, organ damage, and other complications associated with severe dengue. The review notes that diabetes contributes to chronic inflammation, endothelial dysfunction, and impaired immune responses, all of which may worsen the course of dengue infection. The researchers argue that dengue prevention should become part of routine <a href="https://www.healthandme.com/health-wellness/not-just-body-fat-your-muscle-health-may-play-a-larger-role-in-type-2-diabetes-risk-study-finds-article-155101901" data-type="tilCustomLink">diabetes</a> management in countries where dengue is endemic. Lead author Dr. Jothydev Kesavadev, diabetologist, said, "People with Type 2 diabetes represent a particularly vulnerable group during dengue outbreaks. Preventive strategies, including vaccination where appropriate, should become an integral part of diabetes care to reduce severe illness and deaths." <div type="Youtube" id="Oyb1fLG0jU8" title="From U-WIN Success To India's Dengue Vaccine, Immunization Expert Shares Roadmap" thumbUrl="https://i.ytimg.com/vi/Oyb1fLG0jU8/mqdefault.jpg"><url><![CDATA[https://www.youtube.com/watch?v=Oyb1fLG0jU8]]></url></div> The review was co-authored by several diabetes specialists from across India, including Dr. Niti Pall, President-Elect of the International Diabetes Federation Europe. It was presented during the 14th Jothydev's Professional Education Forum Annual Global Diabetes Convention in Kovalam, Kerala, and its publication was formally released by Kerala Health Minister K. Muraleedharan. <h2>Earlier Research </h2> Also read: <a href="https://www.healthandme.com/health-news/dengiall-indias-first-dengue-vaccine-clears-phase-iii-trials-may-soon-enter-markets-article-153411369" data-type="tilCustomLink">DengiAll, India's First Dengue Vaccine Clears Phase III Trials, May Soon Enter Markets</a> While the current paper is a review rather than a new clinical trial, it is supported by a growing body of evidence. A 2024 review published in Health Science Reports found that diabetes is significantly associated with severe dengue, death, elevated liver enzymes, and thrombocytopenia. Similarly, a 2025 review in the International Health journal concluded that accumulating evidence increasingly supports diabetes as an important comorbidity contributing to poor dengue outcomes. <h2>Should People With Diabetes Receive The Recently Approved Dengue Vaccine? </h2> Also read: <a href="https://www.healthandme.com/health-news/indias-first-approved-dengue-vaccine-takedas-qdenga-protects-against-all-four-virus-serotypes-article-155137910" data-type="tilCustomLink">India’s First Approved Dengue Vaccine: Takeda’s QDENGA Protects Against All Four Virus Serotypes</a> The findings come as India recently approved its first dengue vaccine, <a href="https://www.healthandme.com/health-wellness/from-heavy-floods-to-extremely-humid-how-mumbais-extreme-weather-can-impact-your-health-article-155103582" data-type="tilCustomLink">QDENGA</a> (TAK-003). The vaccination should follow national guidelines and individual medical advice. Experts emphasize that vaccination complements, rather than replaces, mosquito bite prevention measures. QDENGA (TAK-003) is a live-attenuated tetravalent dengue vaccine designed to protect against all four dengue virus serotypes. It is administered as two 0.5 mL subcutaneous doses, given three months apart. The vaccine is built on a DENV-2 backbone, incorporating structural proteins from DENV-1, DENV-3 and DENV-4 to provide broad immune protection. The World Health Organization (WHO) recommends QDENGA for use in dengue-endemic settings without the need for pre-vaccination screening. The vaccine is also included in the WHO List of Prequalified Vaccines, allowing procurement through agencies such as UNICEF and PAHO. <h2>Precautions </h2> Experts recommend that people with diabetes: <ul><li>Maintain good <a href="https://www.healthandme.com/health-wellness/aspartame-saccharin-erythritol-linked-to-faster-brain-ageing-study-article-155145056" data-type="tilCustomLink">blood sugar</a> control.</li><li>Avoid mosquito bites by using repellents, long-sleeved clothing, and eliminating stagnant water around homes.</li><li>Seek medical attention immediately if dengue symptoms such as high fever, severe headache, vomiting, abdominal pain, bleeding, or rash develop.</li><li>Discuss dengue vaccination with their healthcare provider if they live in an endemic region and are eligible under national recommendations.</li></ul><meta content="cms.next" name="cmsei" />

do people with type 2 diabetes face a higher risk of severe dengue? new review says yes

Common Antidepressant May Ease One Of Long COVID&#39;s Debilitating Symptoms

common-antidepressant-may-ease-one-of-long-covids-debilitating-symptoms

Common Antidepressant May Ease One Of Long COVID's Debilitating Symptoms

long covid

Antidepressant

Fluvoxamine

Metformin

depression

long covid symptoms

long covid fatigue

A common antidepressant may help millions of people living with long COVID, according to a major international clinical trial that found the medication significantly reduced persistent fatigue, one of the condition's most debilitating symptoms. The findings, published in the Annals of Internal Medicine suggest that fluvoxamine, an selective serotonin reuptake inhibitor (SSRI), could become one of the first evidence-backed treatments specifically targeting long COVID-related fatigue. <h2>Fatigue Due To Long COVID </h2> Even after completely recovering from <a href="https://www.healthandme.com/health-news/fourth-covid-death-reported-in-andhra-pradesh-experts-recommend-boosters-for-high-risk-groups-article-155117381" data-type="tilCustomLink">COVID-19</a> infection, millions continue to experience long COVID, a condition that causes symptoms that last for months or even years. Fatigue is among the most common complaints, often accompanied by brain fog, poor concentration, sleep disturbances and reduced quality of life. Despite the growing burden, there are currently no widely accepted drug treatments for <a href="https://www.healthandme.com/health-news/covid-spikes-in-india-experts-allay-fears-stress-vaccination-and-masks-article-155105011" data-type="tilCustomLink">long COVID fatigue</a>, making the new findings particularly significant. Also read: <a href="https://www.healthandme.com/health-wellness/covid-19-in-india-omicron-rf-5-primarily-affects-throat-unlikely-to-trigger-pneumonia-in-healthy-people-say-experts-article-155138964" data-type="tilCustomLink">COVID-19 In India: Omicron RF.5 Primarily Affects Throat, Unlikely To Trigger Pneumonia In Healthy People, Say Experts</a> <h2>What Did The Study Find? </h2> Researchers conducted a randomized, placebo-controlled clinical trial with 399 adults in Brazil who had experienced long COVID symptoms for at least 90 days after their initial infection. Participants were randomly assigned to receive either: <ul><li>Fluvoxamine</li><li>Metformin</li><li>Placebo</li></ul> After treatment and follow-up, patients taking <a href="https://www.healthandme.com/health-news/omicron-sub-lineages-drive-covid-surge-in-india-why-deaths-are-occurring-article-155088525" data-type="tilCustomLink">fluvoxamine</a> reported significantly lower fatigue scores compared with those receiving placebo. Improvements were observed within the first month and became more pronounced after 60 days. Participants also reported having a better quality of life. On the other hand, Metformin did not show a meaningful benefit for long COVID fatigue in this trial. Serious adverse events were rare, and fluvoxamine was generally well tolerated. Also read: <a href="https://www.healthandme.com/health-news/india-logs-339-covid-19-cases-in-first-half-of-july-what-to-know-about-the-rf-5-omicron-subvariant-article-155137595" data-type="tilCustomLink">India Logs 339 COVID-19 Cases In First Half Of July: What To Know About The RF.5 Omicron Subvariant</a> <h2>About Fluvoxamine </h2> Fluvoxamine is commonly used to treat <a href="https://www.healthandme.com/health-wellness/mood-swings-anxiety-brain-fog-during-menopause-expert-recommends-looking-beyond-hot-flashes-article-155133060" data-type="tilCustomLink">depression </a> and obsessive-compulsive disorder (OCD). Scientists believe its benefits in long COVID may extend beyond its antidepressant effects. The drug is thought to reduce inflammation and influence immune signaling through activation of the sigma-1 receptor, a protein involved in regulating inflammatory responses and cellular stress. These mechanisms have also made fluvoxamine a subject of previous COVID-19 treatment research. Researchers caution, however, that the exact biological mechanism behind its effect on long COVID fatigue remains under investigation. Lead investigator Dr. Gilmar Reis of Pontifical Catholic University of Minas Gerais said the findings represent an important step toward treating one of long COVID's most persistent symptoms. "This trial gives clinicians their first strong evidence for a medication that helps reduce long COVID fatigue." Senior author Dr. Edward Mills, professor at McMaster University, said, "This is an important step forward for patients who have been desperate for evidence-based options." While researchers describe the results as encouraging, they stress that fluvoxamine should not be started without medical supervision. <h2>Long COVID Affects Millions </h2> <div type="Youtube" id="DG1g7Mp8XA4" title="Do You Need Another COVID Booster Shot? Experts Answer After 4 COVID Deaths In Andhra Pradesh" thumbUrl="https://i.ytimg.com/vi/DG1g7Mp8XA4/mqdefault.jpg"><url><![CDATA[https://www.youtube.com/watch?v=DG1g7Mp8XA4]]></url></div> <a href="https://www.healthandme.com/health-wellness/study-decodes-why-covid-survivors-continue-to-suffer-vision-problems-article-155056007" data-type="tilCustomLink">Long COVID</a> is estimated to affect tens of millions of people worldwide, with persistent fatigue preventing patients from carrying out everyday activities. Because fluvoxamine is already widely available, inexpensive and familiar to physicians, experts say positive findings from this trial could help future research and influence treatment strategies if it fairs well in larger studies. Researchers describe the study as one of the strongest pieces of evidence that a medication can effectively reduce long COVID fatigue, offering hope for patients who have been struggling. <meta content="cms.next" name="cmsei" />